Novo Nordisk
Novo Nordisk is a Danish multinational pharmaceutical company that specializes in diabetes care and hormone replacement therapies. Founded in 1923, the company is known for its innovative insulin products and GLP-1 receptor agonists, such as Ozempic, which are used for managing diabetes and aiding in weight loss. Novo Nordisk has a strong commitment to research and development, particularly in the fields of diabetes, obesity, and hemophilia.
Born on Sep 07, 1923 (102 years old)
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Denmark | 1 | 8.00 | 0.08% | +0% | 5,792,202 | 4,368 | $350,000 | 264$ |
| Totals | 1 | 5,792,202 | 4,368 | $350,000 | 264$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Denmark:
Novo Nordisk's weight loss medication is among those recommended by the World Health Organization.
8
Brazil:
Novo Nordisk requested the inclusion of semaglutide in the public health system.
6
Switzerland:
Novo Nordisk is a Danish insulin manufacturer that has faced challenges in meeting growth expectations.
5
Estonia:
Novo Nordisk is being sued by numerous individuals for serious side effects caused by its popular weight loss drug Ozempic.
2
Denmark:
Novo Nordisk is a Danish pharmaceutical giant that has seen significant revenue despite a decline in stock price.
7
Denmark:
Novo Nordisk is discussed regarding its stock performance and expectations for growth.
5
Denmark:
Novo Nordisk is a Danish pharmaceutical giant that has seen significant revenue growth despite a decline in stock price.
7
Denmark:
Novo Nordisk is a pharmaceutical giant that has presented impressive financial results over the years.
8
Denmark:
Novo Nordisk experienced a historic drop in stock value.
4
Canada:
Novo Nordisk is the Danish drugmaker that produces Ozempic and Wegovy.
5